This site is intended for healthcare professionals
Drug information


Read time: 23 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Amiodarone is indicated only for the treatment of severe cardiac rhythm disorders not responding to other therapies or when other treatments cannot be used.

- AV nodal arrhythmias and AV re-entrant tachycardia tachycardia, e.g. as a manifestation of Wolff-Parkinson-White (WPW) syndrome.

- All types of tachyarrhythmias including supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; life-threatening ventricular arrythmias (including persistent or non-persistent ventricular tachycardia or episodes of ventricular fibrillation).

Amiodarone Hydrochloride 30mg/ml injection can be used where a rapid response is required or where oral administration is not possible.

Amiodarone may be used prior to DC cardioversion.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).